The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.

This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX-mediated disorders.

This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX-mediated disorders.

Provided is a compound which accelerates the enzymatic reaction catalyzed by an oxidase. The present invention provides an oxidase reaction accelerating agent comprising a compound represented by formula (I) and a method using the same.

Provided is a compound which accelerates the enzymatic reaction catalyzed by an oxidase. The present invention provides an oxidase reaction accelerating agent comprising a compound represented by formula (I) and a method using the same.

Disclosed are novel pharmaceutical compositions containing 3-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid his-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

Disclosed are novel pharmaceutical compositions containing 3-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2-hydroxy-[1,1-biphenyl]-3-carboxylic acid his-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.

The present invention relates to crystalline form of Eltrombopag free acid and its process for preparation. ##STR00001##

The present invention relates to crystalline form of Eltrombopag free acid and its process for preparation. ##STR00001##

The present disclosure relates to a compound of formula

##STR00001##

or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.